Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Vertex Pharmaceuticals has secured two simultaneous ... along with an additional 31 CF-causing mutations. Trikafta was initially approved in 2019 for patients aged 12 years and older, but has ...

Vertex Pharmaceuticals said Friday the ... in the transmembrane conductance regulator gene or a mutation that is responsive to trikafta based on clinical or in vitro data. With this approval ...

Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations. With this approval, approximately 300 people in the U.S. are newly eligible ...

A new EMA approval has expanded the use of Vertex ... in the US (as Trikafta) and was approved by the European Commission in August. Kaftrio covers a broader set of CFTR mutations spanning 90% ...

Vertex Pharmaceuticals (VRTX ... efficacy in 31 additional mutations, and lower sweat chloride levels than Trikafta, is another step in achieving this goal.” ...

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 ... Every Morning RBC Capital Markets says Vertex management is optimistic about the ...

Vertex Pharmaceuticals Incorporated ... treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO ...